Oncology · Medical Literature
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
Abstract
Background: SYHX2011 is a novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose. This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients with breast cancer. Methods: Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer were randomly assigned to receive SYHX2011 (260 mg/m2) or PAB (260 mg/m2) intravenously once every 3 weeks, stratified by prior taxane use and rash history (prior taxane with rash, prior taxane without rash, or no prior taxane), as well prior lines of chemotherapy for advanced disease (0 or ≥1). The primary endpoint was objective response rate assessed by an independent review committee. Noninferiority was to be declared if the lower bound of the 95% confidence interval (CI) for the rate ratio exceeded 0.75; if the lower bound exceeded 1, superiority would subsequently be tested and considered confirmed. Results: In this multicenter, randomized, double-blind, phase III trial across 56 centers in China, 621 patients were screened between 2023 April 23 and 2024 March 21, of whom 459 patients were randomized to SYHX2011 (n = 229) or PAB (n = 230). The confirmed objective response rate assessed by an independent review committee was 35.8% (95% CI 29.4% to 42.6%) for SYHX2011 and 25.8% (95% CI 20.2% to 32.1%) for PAB (rate ratio = 1.38, 95% CI 1.04 to 1.84; one-sided P = 0.012), indicating that SYHX2011 was noninferior to PAB. The superiority of SYHX2011 over PAB was also confirmed. SYHX2011 showed a lower incidence of rash compared with PAB during the first 2 administration cycles (13.6% vs. 34.3%) and all treatment cycles (16.2% vs. 42.6%). Treatment-related adverse events (TRAEs) occurred in 98.2% of patients receiving SYHX2011 and 98.3% of patients receiving PAB. In the SYHX2011 group, 111 (48.7%) patients experienced grade ≥3 TRAEs, compared with 101 (43.9%) patients in the PAB group. The most common grade ≥3 TRAEs were neutropenia, leukopenia, and peripheral sensory neuropathy. The median investigational drug reconstitution time was 2.0 min for SYHX2011 and 11.0 min for PAB. Conclusions: SYHX2011 demonstrated greater therapeutic benefits than PAB and significantly reduced the incidence of rash. Additionally, it could offer greater convenience in clinical application, providing advanced breast cancer patients with more effective and safer treatment options. Trial registration: ClinicalTrials.gov identifier: NCT05753865. Date of registration: 2023 February 22.
Clinical relevance
Is SYHX2011 — a novel albumin-bound paclitaxel in which most nonparticulate human albumin is replaced with mannitol and sucrose — noninferior (or superior) to standard albumin-bound paclitaxel (PAB/nab-paclitaxel) in objective response rate among patients with unresectable locally advanced or metastatic breast cancer? __SNAPSHOT__ {"studyDesign":"Multicenter, randomized, double-blind, active-controlled, Phase III noninferiority/superiority trial","setting":"56 centers across China; trial dates April 23, 2023 – March 21, 2024","sampleSize":"621 screened; n=459 randomized (SYHX2011: n=229; PAB: n=230)","population":"Adults with histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer; stratified by prior taxane use with/without rash history, and by number of prior chemotherapy lines for advanced disease (0 or ≥1)","intervention":"SYHX2011 260 mg/m² intravenously once every 3 weeks","comparator":"Paclitaxel for injection (albumin-bound; PAB/nab-paclitaxel) 260 mg/m² intravenously once every 3 weeks","primaryOutcome":"Confirmed objective response rate (ORR) assessed by an independent review committee","followUp":"Not reported (duration of treatment exposure not specified in abstract)","fundingSource":"Industry — multiple authors are employees of CSPC Ouyi Pharmaceutical Technology Co., Ltd. (manufacturer of SYHX2011)"}
Key findings
The confirmed ORR by independent review committee was 35.8% (95% CI 29.4%–42.6%) for SYHX2011 versus 25.8% (95% CI 20.2%–32.1%) for PAB, yielding a rate ratio of 1.38 (95% CI 1.04–1.84; one-sided P=0.012). Because the lower bound of the 95% CI for the rate ratio (1.04) exceeded both the noninferiority margin of 0.75 and the superiority threshold of 1.0, both noninferiority and superiority of SYHX2011 over PAB were declared. The absolute difference in ORR was approximately 10 percentage points (calculated), favoring SYHX2011. NNT to achieve one additional response: approximately 10 (calculated; 1/0.10). Regarding safety, treatment-related adverse events (TRAEs) occurred in 98.2% of SYHX2011-treated patients and 98.3% of PAB-treated patients — virtually identical overall TRAE rates. Grade ≥3 TRAEs occurred in 48.7% (111/229) of SYHX2011 patients versus 43.9% (101/230) of PAB patients — a numerically higher rate with SYHX2011, though whether this difference is statistically significant was not reported in the abstract. The most common grade ≥3 TRAEs in both arms were neutropenia, leukopenia, and peripheral sensory neuropathy. A clinically meaningful reduction in rash was observed with SYHX2011 versus PAB: 13.6% vs. 34.3% during the first 2 cycles, and 16.2% vs. 42.6% across all treatment cycles. Median drug reconstitution time was markedly shorter for SYHX2011 (2.0 minutes) versus PAB (11.0 minutes).
Practice implications
This Phase III trial establishes that SYHX2011 meets both noninferiority and superiority criteria versus standard PAB on confirmed ORR — a clinically relevant endpoint in the metastatic setting. The roughly 10 percentage-point absolute improvement in ORR and the significant reduction in rash incidence are meaningful signals, particularly given that rash is a common and bothersome toxicity of nab-paclitaxel. However, several important caveats apply. First, ORR is a surrogate endpoint; progression-free survival (PFS) and overall survival (OS) data are not reported in the abstract, so the durability and survival impact of the observed response advantage are unknown. Second, the trial was conducted exclusively in China across 56 Chinese centers, limiting immediate generalizability to non-Asian populations. Third, the numerically higher grade ≥3 TRAE rate with SYHX2011 (48.7% vs. 43.9%) warrants attention, even though overall TRAE rates were essentially equivalent; statistical testing of this difference was not reported. Fourth, SYHX2011 is manufactured by the trial sponsor, and multiple co-authors are sponsor employees, introducing a meaningful risk of industry bias. Fifth, only the abstract is available to this analysis; full-text data on subgroup analyses, PFS, OS, quality of life, and censoring methodology are not assessable. This summary is therefore based on abstract-only data, which is an important limitation. SYHX2011 appears promising and the data are hypothesis-generating for regulatory review in China; confirmation of PFS/OS benefit and external validation in non-Asian populations would be required before broader adoption. __LIMITATIONS__ ORR is a surrogate endpoint; PFS and OS data not reported in abstract — long-term clinical benefit unestablished.,Trial conducted exclusively in China (56 Chinese centers); findings may not be generalizable to other ethnic or geographic populations.,Strong industry sponsorship risk: multiple listed authors are employees of CSPC Ouyi Pharmaceutical Technology Co., Ltd., the manufacturer of SYHX2011.,Grade ≥3 TRAE rate was numerically higher with SYHX2011 (48.7%) than PAB (43.9%); statistical significance of this difference not reported.,Only the abstract was available for this analysis; full-text subgroup analyses, PFS curves, OS data, quality-of-life measures, and statistical methodology cannot be evaluated.,Noninferiority margin of 0.75 for the rate ratio, while pre-specified, is relatively wide and its clinical justification cannot be assessed from the abstract alone.,Duration of treatment follow-up not reported; sustainability of response advantage is unknown.,No reported data on breast cancer subtypes (HR+/HER2-, HER2+, TNBC) — the relative benefit across molecular subgroups is unknown.,Double-blind design is a strength, but blinding integrity in the context of differential rash rates (16% vs. 43%) may have been compromised. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In this Chinese Phase III trial, SYHX2011 — a novel albumin-bound paclitaxel formulated with mannitol and sucrose rather than human albumin — demonstrated both noninferiority and superiority to standard nab-paclitaxel on confirmed ORR (35.8% vs. 25.8%; rate ratio 1.38, 95% CI 1.04–1.84), with a substantially lower incidence of rash. Survival endpoints (PFS, OS) are not yet reported, industry sponsorship is prominent, and the trial population is exclusively Chinese, limiting generalizability. Clinicians should view these results as regulatory-grade evidence for potential approval in China but should await PFS/OS data and independent replication before considering practice change in broader populations.